COMMUNIQUÉS West-GlobeNewswire

Ipsen va acquérir Memo Therapeutics AG, élargissant son portefeuille de maladies rares grâce à l’ajout d’un anticorps premier de sa classe ciblant le polyomavirus BK
01/07/2026
Acquisition centrée sur le potravitug, un anticorps monoclonal premier de sa classe au stade clinique, ciblant le polyomavirus BK L’ensemble des données issues de l’essai de phase II SAFE KIDNEY II soutient le lancement [...]
Oxford-Harrington Rare Disease Centre Strengthens Rare Childhood Cancer Programme Through Appointment of New Little Princess Trust Professor of Paediatric Oncology
01/07/2026
Professor Isidro Cortés-Ciriano, a n internationally recognised scientist with extensive experience in childhood cancer research, will accelerate Oxford-Harrington’s mission to translate discoveries into new therapies [...]
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
01/07/2026
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes topline results from [...]
Press Release: Availability of the aide-mémoire for Q2 2026 results
01/07/2026
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026 . Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter [...]
Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
01/07/2026
Communiqué de presse Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé La demande d’autorisation de mise sur le [...]
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
01/07/2026
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading [...]
Idorsia appoints Roland Wandeler as Chief Executive Officer
01/07/2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with business acumen to [...]
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
01/07/2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License [...]
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
01/07/2026
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if [...]
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
01/07/2026
SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based [...]
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
30/06/2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
Acquisition of Own Shares
30/06/2026
Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
30/06/2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, [...]
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
30/06/2026
Company announcement No. 29 / 2026 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
30/06/2026
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides DUBLIN, Ireland and BRIDGEWATER, N. [...]
DLH Announces Leadership Transition
30/06/2026
Zach Parker to Retire; Kathryn JohnBull Appointed CEO; Steve Oroho Appointed CFO ATLANTA, June 30, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital [...]
Result of Annual General Meeting
30/06/2026
June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company [...]
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
30/06/2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. [...]
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
30/06/2026
Company announcement – No. 30 / 2026 Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: [...]

Pages